Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of misleading information in its IPO registration statement, particularly regarding the funding timeline for its operations [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Buathongsri v. Zenas BioPharma, Inc. and was filed in the District of Massachusetts [1]. - Investors who purchased Zenas BioPharma securities during its IPO on September 13, 2024, have until June 16, 2025, to seek lead plaintiff status [1][2]. - The lawsuit claims that Zenas BioPharma overstated its operational funding timeline, stating it could fund operations for 24 months instead of the actual 12 months disclosed later [3][4]. Group 2: Financial Impact - Zenas BioPharma sold over 13 million shares at $17.00 per share during its IPO [2]. - As of April 15, 2025, Zenas BioPharma's stock closed at $8.72, representing a 48.7% decline from the IPO price [4]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing the investors in the class action lawsuit and is recognized as a leading law firm in securities fraud litigation [6]. - The firm has a strong track record, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - Rosen Law Firm is reminding investors of Zenas BioPharma, Inc. about a class action lawsuit related to the company's IPO, with a lead plaintiff deadline set for June 16, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Zenas BioPharma securities may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that the Registration Statement contained false and misleading statements regarding Zenas BioPharma's financial status and operational funding [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4]. - The firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - Investors are advised that until a class is certified, they are not represented by counsel unless they retain one [7].

Summary of Zenas BioPharma (ZBIO) 2025 Conference Call Company Overview - Zenas BioPharma is a biotechnology company focused on immunology and inflammation, established approximately five years ago [3][2] - The company is advancing its lead molecule, abexolumab, through various clinical studies [3][4] Key Programs and Milestones - **IgG4 Related Disease Program**: - Fully enrolled with last patient expected out in November, results anticipated by year-end [4][18] - The program targets a disease affecting 30,000 to 40,000 patients in the US and Europe, with a diagnosed prevalence of about 20,000 in each market [10][22] - **Multiple Sclerosis (MS) Program**: - Phase II trial completed enrollment with results expected in early Q4 [4][23] - The study design includes MRI results at twelve weeks, focusing on cumulative new T1 GAD enhancing lesions [23][41] - **Systemic Lupus Erythematosus (SLE) Program**: - Enrolling patients with results expected mid-next year [4][25] - Previous studies indicated a potential 35% benefit over placebo with proper dosing [25][57] Mechanism of Action - Abexolumab targets two markers on B cells: CD19 and FC gamma R2B (CD32B), which inhibits B cell activity [5][6] - The drug is designed to provide continuous exposure and target engagement, potentially leading to better patient outcomes compared to existing therapies like rituximab [15][16] Competitive Landscape - Abexolumab shows a faster onset of action and sustained response compared to rituximab, with a projected flare rate of under 10% versus 50-60% for placebo [18][19] - The market opportunity for IgG4 related disease is estimated at $3 billion in the US and $2 billion in Europe [22] Clinical Data and Expectations - The primary endpoint for the IgG4 related disease trial is time to disease flare, with a strong expectation of favorable results based on previous studies [18][40] - For the MS program, a significant reduction in T1 GAD enhancing lesions is anticipated, correlating with clinical outcomes [41][42] Corporate Strategy and Commercialization - Zenas BioPharma has a well-prepared team for commercialization, with $350 million in funding to support operations through Q4 2026 [65] - The company is exploring additional indications and potential business development opportunities to expand its portfolio [66] Conclusion - Zenas BioPharma is positioned to make significant advancements in the treatment of autoimmune diseases with its lead molecule abexolumab, backed by promising clinical data and a robust commercialization strategy [28][66]

Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of materially false and misleading statements regarding its financial status and operations funding during its initial public offering in September 2024 [2]. Group 1: Allegations - The complaint claims that Zenas BioPharma overstated the duration it could fund its operations with existing cash and expected IPO proceeds [2]. - It is alleged that the public statements made by the defendants were materially false and misleading throughout the relevant period and were negligently prepared [2]. Group 2: Class Action Details - The class period for the lawsuit includes shareholders who purchased ZBIO securities during the time of the IPO [1]. - Shareholders are encouraged to register for the class action by June 16, 2025, to potentially be appointed as lead plaintiffs [3]. - Once registered, shareholders will receive updates on the case through a portfolio monitoring software [3]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - Zenas BioPharma is facing a class action lawsuit due to allegations of misleading information in its IPO registration statement, which has resulted in significant financial losses for investors [1][3][4]. Group 1: Company Overview - Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing and commercializing immunology-based therapies [3]. Group 2: IPO Details - The company sold over 13 million shares at a price of $17.00 each during its IPO [3]. - The IPO registration statement claimed that Zenas BioPharma could fund its operations for 24 months using existing cash and anticipated IPO proceeds [3]. Group 3: Allegations and Financial Impact - The class action lawsuit alleges that the IPO documents were materially false and misleading, particularly regarding the funding timeline [3]. - On November 12, 2024, Zenas BioPharma disclosed in its quarterly report that it could only fund operations for 12 months, contradicting the earlier statement [4]. - As of April 15, 2025, the stock price had dropped to $8.72, representing a decline of 48.7% from the IPO price [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Zenas BioPharma, Inc. regarding a class action lawsuit related to misleading statements made during the company's initial public offering in September 2024 [1][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of individuals who purchased or acquired Zenas BioPharma securities during the specified class period [3]. - Allegations include that Zenas BioPharma materially overstated its ability to fund operations with existing cash and expected net proceeds from the IPO, leading to false and misleading public statements [4]. - The deadline for shareholders to register for the class action is June 16, 2025, and there is no cost or obligation to participate [5]. Group 2: Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [6]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zenas BioPharma, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's financial status and operational funding [3][5]. Group 1: Legal Investigation - The firm is reminding investors of the June 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Zenas [3]. - The complaint alleges that Zenas BioPharma overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to materially false and misleading public statements [5]. Group 2: Investor Communication - Faruqi & Faruqi encourages investors who suffered losses in Zenas to contact them directly to discuss their legal options [1]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Zenas' conduct [7].

Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of misleading information in its IPO registration statement, particularly regarding its financial sustainability and operational funding timeline [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit, titled Buathongsri v. Zenas BioPharma, Inc., allows investors who purchased Zenas BioPharma securities during its IPO on September 13, 2024, to seek lead plaintiff status by June 16, 2025 [1][5]. - The lawsuit claims that Zenas BioPharma overstated its ability to fund operations, stating it could sustain for 24 months instead of the actual 12 months disclosed later [3][4]. - As of April 15, 2025, Zenas BioPharma's stock price was $8.72, which is 48.7% lower than the IPO price of $17.00 per share [4]. Group 2: Company Background - Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immunology-based therapies [2]. - The company sold over 13 million shares at $17.00 each during its IPO [2]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing the investors in the class action lawsuit and is recognized as a leading law firm in securities fraud litigation [6]. - The firm has a strong track record, having recovered over $2.5 billion for investors in 2024 alone, and has been ranked 1 in securities class action services for four out of the last five years [6].

Core Viewpoint - Rosen Law Firm is reminding investors of Zenas BioPharma, Inc. about the June 16, 2025 deadline to become a lead plaintiff in a securities class action lawsuit related to the company's September 2024 IPO [1][5]. Group 1: Legal Action Details - Investors who purchased Zenas BioPharma securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 16, 2025 [3]. - The lawsuit alleges that the Registration Statement contained false and misleading statements regarding the company's financial sustainability and operational funding [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zenas BioPharma, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's financial status and operational funding [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Zenas to contact them for discussions regarding their legal rights [1]. - A federal securities class action has been filed against Zenas, with a deadline of June 16, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Zenas materially overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to misleading public statements [4]. Group 2: Class Action Details - The lead plaintiff in a class action is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [5]. - Any member of the class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [5]. Group 3: Additional Information - Faruqi & Faruqi encourages anyone with information regarding Zenas' conduct, including whistleblowers and former employees, to reach out to the firm [6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].